Spring direct naar de hoofdnavigatie of de inhoud

Mark Einerhand

Patent attorney

“In the end it's all about the value that the patent adds to the product.”
Home / Experts / Mark Einerhand

Mark Einerhand

  • Life Sciences
  • European Patent Attorney
  • Dutch Patent Attorney
  • Partner

Mark Einerhand has been active in the patent world since 1998, when he made the switch from a biotech startup to V.O.

Mark’s career started in science. After his studies of molecular biology at the University of Amsterdam, he took his PhD in medical science inLeiden, in 1992. He was a visiting scientist at Cornell University in New York and the MRC at Mill Hill in London.

More information about Mark

His particular expertise lies in the field of medical (bio)technology, diagnostics and medicines. Because of his background at Introgene/Crucell, Mark has a special affinity with Life Science startups. He has a wide experience in patent cases before the court in The Hague.

Working experience

  • Patent Attorney, V.O. (1998-present)
  • IntroGene (now Crucell), Rijswijk (1995)
  • Post-Doc at Leiden University (1993)
  • Medical Research Council, Mill Hill, London (1992)
  • Visiting Scientist, Cornell University New York (1992)

Education

  • PhD in Medicine, Leiden University (1992)
  • MSc in Biochemistry, University of Amsterdam (1987), Major in Molecular Oncology, Dutch Cancer Institute

Publications

  • Co-author of article ‘The patentability of stem cells in Europe’, IAM Life Sciences 2015.
    Einerhand, M.P.W. (2011): Advance offering of generics found to infringe. Managing Intellectual Property: Vol 205: page: 87.
  • Einerhand M.P.W. (2010): A contribution to: Legal and intellectual property issues associated with stem cells. In: Stem Cells; scientific facts and fiction, (C. Mummery; I. Wilnut, A van de Stolpe and
    B.A.J. Roelen), Academic Press: Elsevier.
  • Einerhand M.P.W. and van Melle, J (2004): Patenting of inventions in the field of bio-informatics.
    In: The new avenues in Bioinformatics, (Seckbach, J and Rubin, E eds), Kluwer Academic Publishers, the Netherlands.
  • Principle inventor on Patents and Patent Applications: Einerhand, M.P.W. and Valerio (1997). WO 98/32870: US 6,232,105: A conditional replication and expression system. Einerhand, M.P.W. and Valerio (1997). WO 99/32647: Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into chromosomal DNA of target cells in gene therapy. Einerhand, M.P.W. and Valerio (1996). WO98/24924: NZ 336185:
  • Transduction of primate hemopoietic repopulating stem cells. Einerhand, M.P.W. and Valerio (1995). WO 97/20943: US 6,140,103: Regulated protein expression in stably transfected mammalian cells. Einerhand, M.P.W. (1992) Gene transfer into hemopoietic stem cells: prospects for human gene therapy. University of Leiden.

Professional & Community Activities

  • Member of the Steering Committee World IP Forum 2015
    Former member of the European Qualifying Examination committee III

Languages

  • English
  • Dutch
  • German

Also see these experts

Wezenbeek, Bart van

Bart van Wezenbeek

  • European Patent Attorney
  • Dutch Patent Attorney
  • Senior Associate

Hajo Kraak

  • European Patent Attorney
  • Dutch Patent Attorney
  • Partner
More experts

News

Infringement by equivalence

It is one of the most challenging subjects in the field of patents – equivalence. Henri van Kalkeren, patent attorney at V.O., explains: ‘Recent decisions of judges therefore remain relevant to us. It is and remains a relatively grey area.’Continue reading

Platform Formalities Officers increases level of administration

In various European countries, there is a great deal of enthusiasm about the approach and method of the Platform Formalities Officers (PFO). In less than ten years, the PFO has developed into a respected platform. High time to find out a bit more about it. Ronald van Egmond, PFO board member and business support senior […]Continue reading

United Kingdom approves Unified Patent Court

The UK has given its final approval of the new Unified Patent Court (UPC) and the new Unitary Patent on 26 April 2018.Continue reading